促卵泡素α/促黄体素α在辅助生殖技术中的疗效与安全性:一项针对卵巢低反应患者的随机对照试验
这项III期单盲随机对照试验纳入939例卵巢低反应患者,比较固定比例重组人促卵泡素/促黄体素复方与单用促卵泡素的疗效与安全性。主要终点获卵数两组无显著差异;事后分析显示复方组总妊娠结局失败率更低(OR 0.52),中重度卵巢低反应者活产率更高,但研究未针对这些终点设计效能。
要点
- 主要终点获卵数两组无显著差异,复方组与单药组安全性均良好。
- 事后分析示复方组总妊娠结局失败率6.7%低于单药组12.4%,OR 0.52。
- 事后分析示中重度卵巢低反应者复方组活产率更高,轻度者单药组更高。
核心结论
- 在本研究卵巢低反应人群中,复方与单药刺激后获卵数相似,但事后分析显示复方组总妊娠结局失败率更低,且中重度卵巢低反应者活产率更高,这些发现需进一步研究。
- 两种方案的获益风险平衡均为正向。
研究设计与样本
- III期、单盲、阳性对照、随机、平行组临床试验,患者随访一个辅助生殖技术周期。
- 共939例患者按1:1随机接受复方或单药,随机按研究中心和年龄分层,采用交互语音应答系统。
- 患者依据包含ESHRE Bologna标准的 criteria 归类为卵巢低反应,采用长方案GnRH激动剂降调节后随机。
主要发现
- 意向治疗人群中,复方组平均获卵数3.3(SD 2.71)vs 单药组3.6(SD 2.82),组间差异无统计学意义。
- 复方组 vs 单药组:生化妊娠率17.3% vs 23.9%,临床妊娠率14.1% vs 16.8%,持续妊娠率11.0% vs 12.4%,活产率10.6% vs 11.7%。
- 事后logistic回归显示总妊娠结局失败率复方组6.7% vs 单药组12.4%,OR 0.52(95%CI 0.33, 0.82;P=0.005)。
- 治疗中出现的不良事件总比例复方组19.9% vs 单药组26.8%,未见与任一治疗相关的持续性不良事件模式。
关键数值与推荐
- 主要疗效终点为控制性卵巢刺激后获卵数。
- 安全性终点包括不良事件发生率,包括卵巢过度刺激综合征。
临床怎么用
- 作者认为这些发现具有临床相关性,需进一步研究。
- 作者认为复方或单药治疗的获益风险平衡均为正向。
局限性
- 尽管纳入标准采用包含ESHRE Bologna标准的卵巢低反应定义,仍需进一步研究确定Bologna人群中卵巢低反应异质性的影响。
- 与卵巢低反应相关的基线临床特征和活产率之间的相关性,以及组间总妊娠结局失败的差异均来自事后分析,研究未针对这些终点设计效能。
- 本试验中妊娠结局的脱落率可能不反映一般医疗实践。
- 患者人群以白人为主,结果可能不适用于其他种族。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How does the efficacy and safety of a fixed-ratio combination of recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH) compare with that of r-hFSH monotherapy for controlled ovarian stimulation (COS) in patients with poor ovarian response (POR)? SUMMARY ANSWER: The primary and secondary efficacy endpoints were comparable between treatment groups and the safety profile of both treatment regimens was favourable. WHAT IS KNOWN ALREADY: Although meta-analyses of clinical trials have suggested some beneficial effect on reproductive outcomes with r-hLH supplementation in patients with POR, the definitions of POR were heterogeneous and limit the comparability across studies. STUDY DESIGN, SIZE, DURATION: Phase III, single-blind, active-comparator, randomized, parallel-group clinical trial. Patients were followed for a single ART cycle. A total of 939 women were randomized (1:1) to receive either r-hFSH/r-hLH or r-hFSH. Randomization, stratified by study site and participant age, was conducted via an interactive voice response system. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women classified as having POR, based on criteria incorporating the ESHRE Bologna criteria, were down-regulated with a long GnRH agonist protocol and following successful down-regulation were randomized (1:1) to COS with r-hFSH/r-hLH or r-hFSH alone. The primary efficacy endpoint was the number of oocytes retrieved following COS. Safety endpoints included the incidence of adverse events, including ovarian hyperstimulation syndrome (OHSS). Post hoc analyses investigated safety outcomes and correlations between live birth and baseline characteristics (age and number of oocytes retrieved in previous ART treatment cycles or serum anti-Müllerian hormone (AMH)). The significance of the treatment effect was tested by generalized linear models (Poisson regression for counts and logistic regression for binary endpoints) adjusting for age and country. MAIN RESULTS AND THE ROLE OF CHANCE: Of 949 subjects achieving down-regulation, 939 were randomized to r-hFSH/r-hLH (n = 477) or r-hFSH (n = 462) and received treatment. Efficacy assessment: In the intention-to-treat (ITT) population, the mean (SD) number of oocytes retrieved (primary endpoint) was 3.3 (2.71) in the r-hFSH/r-hLH group compared with 3.6 (2.82) in the r-hFSH group (between-group difference not statistically significant). The observed difference between treatment groups (r-hFSH/r-hLH and r-hFSH, respectively) for efficacy outcomes decreased over the course of pregnancy (biochemical pregnancy rate: 17.3% versus 23.9%; clinical pregnancy rate: 14.1% versus 16.8%; ongoing pregnancy rate: 11.0% versus 12.4%; and live birth rate: 10.6% versus 11.7%). An interaction (identified post hoc) between baseline characteristics related to POR and treatment effect was noted for live birth, with r-hFSH/r-hLH associated with a higher live birth rate for patients with moderate or severe POR, whereas r-hFSH was associated with a higher live birth rate for those with mild POR. A post hoc logistic regression analysis indicated that the incidence of total pregnancy outcome failure was lower in the r-hFSH/r-hLH group (6.7%) compared with the r-hFSH group (12.4%) with an odds ratio of 0.52 (95% CI 0.33, 0.82; P = 0.005). Safety assessment: The overall proportion of patients with treatment-emergent adverse events (TEAEs) occurring during or after r-hFSH/r-hLH or r-hFSH use (stimulation or post-stimulation phase) was 19.9% and 26.8%, respectively. There was no consistent pattern of TEAEs associated with either treatment. LIMITATIONS, REASONS FOR CAUTION: Despite using inclusion criteria for POR incorporating the ESHRE Bologna criteria, further investigation is needed to determine the impact of the heterogeneity of POR in the Bologna patient population. The observed correlation between baseline clinical characteristics related to POR and live birth rate, as well as the observed differences between groups regarding total pregnancy outcome failure were from post hoc analyses, and the study was not powered for these endpoints. In addition, the attrition rate for pregnancy outcomes in this trial may not reflect general medical practice. Furthermore, as the patient population was predominantly White these results might not be applicable to other ethnicities. WIDER IMPLICATIONS OF THE FINDINGS: In the population of women with POR investigated in this study, although the number of oocytes retrieved was similar following stimulation with either a fixed-ratio combination of r-hFSH/r-hLH or r-hFSH monotherapy, post hoc analyses showed that there was a lower rate of total pregnancy outcome failure in patients receiving r-hFSH/r-hLH, in addition to a higher live birth rate in patients with moderate and severe POR. These findings are clinically relevant and require additional investigation. The benefit:risk balance of treatment with either r-hFSH/r-hLH or r-hFSH remains positive. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Merck KGaA, Darmstadt, Germany. P.H. has received honoraria for lectures and unrestricted research grants from Ferring, Merck KGaA and MSD. D.R. is a former employee of EMD Serono, a business of Merck KGaA, Darmstadt, Germany. J.S., J.H. and W.C. are employees of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany. T.D.'H. and S.L. are employees of Merck KGaA, Darmstadt, Germany. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT02047227; EudraCT Number: 2013-003817-16. TRIAL REGISTRATION DATE: ClinicalTrials.gov: 24 January 2014; EudraCT: 19 December 2013. DATE OF FIRST PATIENT'S ENROLMENT: 30 January 2014.
引用
- Humaidan P, Chin W, Rogoff D, et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017. PMID: 28137754. doi:10.1093/humrep/dew360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。